IL1B and colitis: Treatment with VAS2870 ameliorated DSS-induced colitis with a reduction in DAI, MPO levels, macroscopic and histological scores, secretion of proinflammatory cytokines (TNF-α, IL-6, and IL-1β), and an increase in colon length, which were not affected by SS treatment (Figure 1A–I).